Inflammatory status and ASCVD risk across dual-axis lipid phenotypes defined by apolipoprotein B and the LDL-C to total cholesterol ratio: UK Biobank

A dual-axis lipid framework combining apolipoprotein B (ApoB) with the low-density lipoprotein cholesterol to total cholesterol ratio (LDL-C/TC) characterizes atherogenic particle burden and cholesterol composition. Whether associations of these phenotypes with atherosclerotic cardiovascular disease (ASCVD) differ by inflammatory status remains uncertain. We analyzed 284,251 UK Biobank participants without cardiovascular disease who were not receiving lipid-lowering therapy at baseline. Phenotypes were defined by ApoB ( < 90 vs ≥90 mg/dL) and LDL-C/TC ( < 0.60 vs ≥0.60). Associations with incident ASCVD were evaluated using multivariable Cox models across high-sensitivity C-reactive protein (hsCRP) and glycoprotein acetyls (GlycA) strata. Exploratory analyses assessed combined lipid and inflammatory marker burden among participants with Systematic Coronary Risk Evaluation 2 (SCORE2) < 10%. During a median 14-year follow-up, 13,535 ASCVD events occurred. Compared with the dual-normal phenotype, adjusted hazard ratios were 1.08 (95% confidence interval [CI], 1.00–1.15) for low-ApoB/high-ratio, 0.98 (0.90–1.06) for high-ApoB/low-ratio, and 1.23 (1.17–1.29) for dual-elevated phenotypes. Phenotype associations differed by binary hsCRP status (P for interaction = 0.010): for the dual-elevated phenotype, the adjusted hazard ratio was 1.28 (1.20–1.37) with hsCRP <2 mg/L and 1.09 (1.01–1.18) with hsCRP ≥2 mg/L. Nevertheless, ASCVD incidence was higher with hsCRP ≥2 mg/L than with hsCRP <2 mg/L (4.6 vs 3.0 per 1,000 person-years). Effect modification was not reproduced using three clinical hsCRP categories (P for interaction = 0.480) or GlycA strata (P for interaction = 0.940). Among participants with SCORE2 < 10%, the 10-year absolute risk difference versus those with no elevated markers increased from 0.46% with one elevated marker to 2.01% with four. The dual-elevated association persisted after adjustment for high-density lipoprotein cholesterol but was largely attenuated after adjustment for non–high-density lipoprotein cholesterol. Dual-axis lipid phenotypes were associated with heterogeneous ASCVD risk. Higher inflammatory burden consistently marked greater absolute risk, whereas modification of relative lipid-associated risk was limited to the binary hsCRP definition and was not reproduced with alternative inflammatory classifications. The phenotype associations overlapped substantially with conventional lipid components, and exploratory combined-marker analyses identified residual absolute-risk heterogeneity without establishing incremental predictive or clinical utility.

Authors

Institutions

Publication Details

Journal
BMC Cardiovascular Disorders
Published
2026-11-17
DOI
https://doi.org/10.1186/s12872-026-06986-0
Primary Topic
Lipoproteins and Cardiovascular Health
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Inflammatory status and ASCVD risk across dual-axis lipid phenotypes defined by apolipoprotein B and the LDL-C to total cholesterol ratio: UK Biobank

Bin Wang, Dong Li
6 links
BMC Cardiovascular Disorders
Lipoproteins and Cardiovascular Health
article

Inflammatory status and ASCVD risk across dual-axis lipid phenotypes defined by apolipoprotein B and the LDL-C to total cholesterol ratio: UK Biobank

Bin Wang, Dong Li
article en

Abstract

A dual-axis lipid framework combining apolipoprotein B (ApoB) with the low-density lipoprotein cholesterol to total cholesterol ratio (LDL-C/TC) characterizes atherogenic particle burden and cholesterol composition. Whether associations of these phenotypes with atherosclerotic cardiovascular disease (ASCVD) differ by inflammatory status remains uncertain. We analyzed 284,251 UK Biobank participants without cardiovascular disease who were not receiving lipid-lowering therapy at baseline. Phenotypes were defined by ApoB ( < 90 vs ≥90 mg/dL) and LDL-C/TC ( < 0.60 vs ≥0.60). Associations with incident ASCVD were evaluated using multivariable Cox models across high-sensitivity C-reactive protein (hsCRP) and glycoprotein acetyls (GlycA) strata. Exploratory analyses assessed combined lipid and inflammatory marker burden among participants with Systematic Coronary Risk Evaluation 2 (SCORE2) < 10%. During a median 14-year follow-up, 13,535 ASCVD events occurred. Compared with the dual-normal phenotype, adjusted hazard ratios were 1.08 (95% confidence interval [CI], 1.00–1.15) for low-ApoB/high-ratio, 0.98 (0.90–1.06) for high-ApoB/low-ratio, and 1.23 (1.17–1.29) for dual-elevated phenotypes. Phenotype associations differed by binary hsCRP status (P for interaction = 0.010): for the dual-elevated phenotype, the adjusted hazard ratio was 1.28 (1.20–1.37) with hsCRP <2 mg/L and 1.09 (1.01–1.18) with hsCRP ≥2 mg/L. Nevertheless, ASCVD incidence was higher with hsCRP ≥2 mg/L than with hsCRP <2 mg/L (4.6 vs 3.0 per 1,000 person-years). Effect modification was not reproduced using three clinical hsCRP categories (P for interaction = 0.480) or GlycA strata (P for interaction = 0.940). Among participants with SCORE2 < 10%, the 10-year absolute risk difference versus those with no elevated markers increased from 0.46% with one elevated marker to 2.01% with four. The dual-elevated association persisted after adjustment for high-density lipoprotein cholesterol but was largely attenuated after adjustment for non–high-density lipoprotein cholesterol. Dual-axis lipid phenotypes were associated with heterogeneous ASCVD risk. Higher inflammatory burden consistently marked greater absolute risk, whereas modification of relative lipid-associated risk was limited to the binary hsCRP definition and was not reproduced with alternative inflammatory classifications. The phenotype associations overlapped substantially with conventional lipid components, and exploratory combined-marker analyses identified residual absolute-risk heterogeneity without establishing incremental predictive or clinical utility.

BMC Cardiovascular Disorders
Beijing Tsinghua Chang Gung Hospital (CN), Tsinghua University (CN)
National Key Research and Development Program of China
Good health and well-being
Lipoproteins and Cardiovascular Health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon